132 related articles for article (PubMed ID: 18240243)
1. Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes.
Lorenzi AR; Clarke AM; Wooldridge T; Waldmann H; Hale G; Symmons D; Hazleman BL; Isaacs JD
Arthritis Rheum; 2008 Feb; 58(2):370-5. PubMed ID: 18240243
[TBL] [Abstract][Full Text] [Related]
2. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia.
Isaacs JD; Greer S; Sharma S; Symmons D; Smith M; Johnston J; Waldmann H; Hale G; Hazleman BL
Arthritis Rheum; 2001 Sep; 44(9):1998-2008. PubMed ID: 11592360
[TBL] [Abstract][Full Text] [Related]
3. Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.
Anderson AE; Lorenzi AR; Pratt A; Wooldridge T; Diboll J; Hilkens CM; Isaacs JD
Rheumatology (Oxford); 2012 Aug; 51(8):1397-406. PubMed ID: 22447884
[TBL] [Abstract][Full Text] [Related]
4. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Hill-Cawthorne GA; Button T; Tuohy O; Jones JL; May K; Somerfield J; Green A; Giovannoni G; Compston DA; Fahey MT; Coles AJ
J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):298-304. PubMed ID: 22056965
[TBL] [Abstract][Full Text] [Related]
5. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study.
Isaacs JD; Manna VK; Rapson N; Bulpitt KJ; Hazleman BL; Matteson EL; St Clair EW; Schnitzer TJ; Johnston JM
Br J Rheumatol; 1996 Mar; 35(3):231-40. PubMed ID: 8620297
[TBL] [Abstract][Full Text] [Related]
6. The number of circulating recent thymic emigrants is severely reduced 1 year after a single dose of alemtuzumab in renal transplant recipients.
Scarsi M; Bossini N; Malacarne F; Valerio F; Sandrini S; Airò P
Transpl Int; 2010 Aug; 23(8):786-95. PubMed ID: 20136785
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.
Ponchel F; Verburg RJ; Bingham SJ; Brown AK; Moore J; Protheroe A; Short K; Lawson CA; Morgan AW; Quinn M; Buch M; Field SL; Maltby SL; Masurel A; Douglas SH; Straszynski L; Fearon U; Veale DJ; Patel P; McGonagle D; Snowden J; Markham AF; Ma D; van Laar JM; Papadaki HA; Emery P; Isaacs JD
Arthritis Res Ther; 2005; 7(1):R80-92. PubMed ID: 15642146
[TBL] [Abstract][Full Text] [Related]
8. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
9. Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies.
Cooles FA; Anderson AE; Drayton T; Harry RA; Diboll J; Munro L; Thalayasingham N; Östör AJ; Isaacs JD
Arthritis Res Ther; 2016 Dec; 18(1):302. PubMed ID: 27993172
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab in Sézary syndrome: efficient but not innocent.
Ure UB; Ar MC; Salihoglu A; Guner SI; Baran A; Oguz O; Ferhanoglu B
Eur J Dermatol; 2007; 17(6):525-9. PubMed ID: 17951134
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
Keating MJ; Flinn I; Jain V; Binet JL; Hillmen P; Byrd J; Albitar M; Brettman L; Santabarbara P; Wacker B; Rai KR
Blood; 2002 May; 99(10):3554-61. PubMed ID: 11986207
[TBL] [Abstract][Full Text] [Related]
12. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.
Cortelezzi A; Pasquini MC; Gardellini A; Gianelli U; Bossi A; Reda G; Sarina B; Musto P; Barcellini W; Neri A; Deliliers GL
Leukemia; 2009 Nov; 23(11):2027-33. PubMed ID: 19641526
[TBL] [Abstract][Full Text] [Related]
13. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
14. Typhlitis as a complication of alemtuzumab therapy.
Marie I; Robaday S; Kerleau JM; Jardin F; Levesque H
Haematologica; 2007 May; 92(5):e62-3. PubMed ID: 17562596
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
16. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
[TBL] [Abstract][Full Text] [Related]
17. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Br J Haematol; 2009 Jan; 144(1):78-85. PubMed ID: 19016731
[TBL] [Abstract][Full Text] [Related]
19. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR
Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413
[TBL] [Abstract][Full Text] [Related]
20. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
